-
1
-
-
33748065304
-
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition
-
McCabe N. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-15.
-
(2006)
Cancer Res
, vol.66
, pp. 8109-8115
-
-
McCabe, N.1
-
2
-
-
17244375049
-
Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase
-
Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005;434:913-7.
-
(2005)
Nature
, vol.434
, pp. 913-917
-
-
Bryant, H.E.1
Schultz, N.2
Thomas, H.D.3
Parker, K.M.4
Flower, D.5
Lopez, E.6
-
3
-
-
67650471685
-
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
-
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
-
(2009)
N Engl J Med
, vol.361
, pp. 123-134
-
-
Fong, P.C.1
Boss, D.S.2
Yap, T.A.3
Tutt, A.4
Wu, P.5
Mergui-Roelvink, M.6
-
4
-
-
77955019276
-
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial
-
Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376: 235-44.
-
(2010)
Lancet
, vol.376
, pp. 235-244
-
-
Tutt, A.1
Robson, M.2
Garber, J.E.3
Domchek, S.M.4
Audeh, M.W.5
Weitzel, J.N.6
-
5
-
-
77955039099
-
Oral poly(ADP-ribose) polymerase inhibitor ola-parib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial
-
Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor ola-parib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-51.
-
(2010)
Lancet
, vol.376
, pp. 245-251
-
-
Audeh, M.W.1
Carmichael, J.2
Penson, R.T.3
Friedlander, M.4
Powell, B.5
Bell-McGuinn, K.M.6
-
6
-
-
35948968410
-
Targeting poly(ADP-ribose) polymerase: A two-armed strategy for cancer therapy
-
Plummer ER, Calvert H. Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy. Clin Cancer Res 2007;13: 6252-6.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 6252-6256
-
-
Plummer, E.R.1
Calvert, H.2
-
7
-
-
79960150694
-
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
-
Johnson N, Li Y-C, Walton ZE, Cheng KA, Li D, Rodig SJ, et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 2011;17:875-82.
-
(2011)
Nat Med
, vol.17
, pp. 875-882
-
-
Johnson, N.1
Li, Y.-C.2
Walton, Z.E.3
Cheng, K.A.4
Li, D.5
Rodig, S.J.6
-
8
-
-
79952747328
-
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
-
Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A 2011;108:3406-11.
-
(2011)
Proc Natl Acad Sci u S A
, vol.108
, pp. 3406-3411
-
-
Patel, A.G.1
Sarkaria, J.N.2
Kaufmann, S.H.3
-
9
-
-
77953916351
-
Rad51C is essential for embryonic development and haploinsufficiency causes increased DNA damage sensitivity and genomic instability
-
Smeenk G, de Groot AJ, Romeijn RJ, van Buul PP, Zdzienicka MZ, Mullenders LH, et al. Rad51C is essential for embryonic development and haploinsufficiency causes increased DNA damage sensitivity and genomic instability. Mutat Res 2010;689:50-8.
-
(2010)
Mutat Res
, vol.689
, pp. 50-58
-
-
Smeenk, G.1
De Groot, A.J.2
Romeijn, R.J.3
Van Buul, P.P.4
Zdzienicka, M.Z.5
Mullenders, L.H.6
-
10
-
-
59149088203
-
Loss of Rad51c leads to embryonic lethality and modulation of Trp53-dependent tumorigenesis in mice
-
Kuznetsov SG, Haines DC, Martin BK, Sharan SK. Loss of Rad51c leads to embryonic lethality and modulation of Trp53-dependent tumorigenesis in mice. Cancer Res 2009;69:863-72.
-
(2009)
Cancer Res
, vol.69
, pp. 863-872
-
-
Kuznetsov, S.G.1
Haines, D.C.2
Martin, B.K.3
Sharan, S.K.4
-
11
-
-
33847350610
-
RAD51C deficiency in mice results in early prophase I arrest in males and sister chromatid separation at metaphase II in females
-
Kuznetsov S, Pellegrini M, Shuda K, Fernandez-Capetillo O, Liu Y, Martin BK, et al. RAD51C deficiency in mice results in early prophase I arrest in males and sister chromatid separation at metaphase II in females. J Cell Biol 2007;176:581-92.
-
(2007)
J Cell Biol
, vol.176
, pp. 581-592
-
-
Kuznetsov, S.1
Pellegrini, M.2
Shuda, K.3
Fernandez-Capetillo, O.4
Liu, Y.5
Martin, B.K.6
-
12
-
-
0037205472
-
Role of mammalian RAD51L2 (RAD51C) in recombination and genetic stability
-
French CA. Role of mammalian RAD51L2 (RAD51C) in recombination and genetic stability. J Biol Chem 2002;277:19322-30.
-
(2002)
J Biol Chem
, vol.277
, pp. 19322-19330
-
-
French, C.A.1
-
13
-
-
66149151303
-
RAD51C facilitates checkpoint signaling by promoting CHK2 phos-phorylation
-
Badie S, Liao C, Thanasoula M, Barber P, Hill MA, Tarsounas M. RAD51C facilitates checkpoint signaling by promoting CHK2 phos-phorylation. J Cell Biol 2009;185:587-600.
-
(2009)
J Cell Biol
, vol.185
, pp. 587-600
-
-
Badie, S.1
Liao, C.2
Thanasoula, M.3
Barber, P.4
Hill, M.A.5
Tarsounas, M.6
-
14
-
-
30444445118
-
Interplay between human DNA repair proteins at a unique double-strand break in vivo
-
Rodrigue A, Lafrance M, Gauthier MC, McDonald D, Hendzel M, West SC, et al. Interplay between human DNA repair proteins at a unique double-strand break in vivo. Embo J 2006;25:222-31.
-
(2006)
Embo J
, vol.25
, pp. 222-231
-
-
Rodrigue, A.1
Lafrance, M.2
Gauthier, M.C.3
McDonald, D.4
Hendzel, M.5
West, S.C.6
-
17
-
-
33845734986
-
BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations
-
Ahn SH, Son BH, Yoon K-S, Noh D-Y, Han W, Kim S-W, et al. BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations. Cancer Lett 2007;245:90-5.
-
(2007)
Cancer Lett
, vol.245
, pp. 90-95
-
-
Ahn, S.H.1
Son, B.H.2
Yoon, K.-S.3
Noh, D.-Y.4
Han, W.5
Kim, S.-W.6
-
18
-
-
84875512435
-
The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines
-
Nam H-J, Kim H-P, Yoon Y-K, Song S-H, Min A-R, Han S-W, et al. The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines. Invest New Drugs 2012;30:2148-60.
-
(2012)
Invest New Drugs
, vol.30
, pp. 2148-2160
-
-
Nam, H.-J.1
Kim, H.-P.2
Yoon, Y.-K.3
Song, S.-H.4
Min, A.-R.5
Han, S.-W.6
-
19
-
-
55949092708
-
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
-
Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AOH, Zander SAL, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008;105: 17079-84.
-
(2008)
Proc Natl Acad Sci u S A
, vol.105
, pp. 17079-17084
-
-
Rottenberg, S.1
Jaspers, J.E.2
Kersbergen, A.3
Van Der Burg, E.4
Nygren, A.O.H.5
Zander, S.A.L.6
-
20
-
-
33947380240
-
Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology
-
Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007;13: 1383-8.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 1383-1388
-
-
Ratnam, K.1
Low, J.A.2
-
21
-
-
65949095892
-
Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin
-
Hay T, Matthews JR, Pietzka L, Lau A, Cranston A, Nygren AOH, et al. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 2009;69:3850-5.
-
(2009)
Cancer Res
, vol.69
, pp. 3850-3855
-
-
Hay, T.1
Matthews, J.R.2
Pietzka, L.3
Lau, A.4
Cranston, A.5
Nygren, A.O.H.6
-
22
-
-
33644826522
-
The polycomb group protein EZH2 impairs DNA repair in breast epithelial cells
-
Zeidler M, Varambally S, Cao Q, Chinnaiyan AM, Ferguson DO, Merajver SD, et al. The polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. Neoplasia 2005;7:1011-9.
-
(2005)
Neoplasia
, vol.7
, pp. 1011-1019
-
-
Zeidler, M.1
Varambally, S.2
Cao, Q.3
Chinnaiyan, A.M.4
Ferguson, D.O.5
Merajver, S.D.6
-
23
-
-
33751282001
-
The polycomb group protein enhancer of Zeste 2: Its links to DNA repair and breast cancer
-
Zeidler M, Kleer CG. The polycomb group protein enhancer of Zeste 2: its links to DNA repair and breast cancer. J Mol Histol 2006;37:219-23.
-
(2006)
J Mol Histol
, vol.37
, pp. 219-223
-
-
Zeidler, M.1
Kleer, C.G.2
-
24
-
-
84861474647
-
EZH2-mediated epigenetic repression of DNA repair in promoting breast tumor initiating cells
-
Stefansson OA, Esteller M. EZH2-mediated epigenetic repression of DNA repair in promoting breast tumor initiating cells. Breast Cancer Res 2011;13:309.
-
(2011)
Breast Cancer Res
, vol.13
, pp. 309
-
-
Stefansson, O.A.1
Esteller, M.2
-
25
-
-
17244373777
-
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
-
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
-
(2005)
Nature
, vol.434
, pp. 917-921
-
-
Farmer, H.1
McCabe, N.2
Lord, C.J.3
Tutt, A.N.4
Johnson, D.A.5
Richardson, T.B.6
-
26
-
-
80052389761
-
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study
-
Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852-61.
-
(2011)
Lancet Oncol
, vol.12
, pp. 852-861
-
-
Gelmon, K.A.1
Tischkowitz, M.2
Mackay, H.3
Swenerton, K.4
Robidoux, A.5
Tonkin, K.6
-
27
-
-
33644640440
-
Arabidopsis RAD51C gene is important for homologous recombination in meiosis and mitosis
-
Abe K, Osakabe K, Nakayama S, Endo M, Tagiri A, Todoriki S, et al. Arabidopsis RAD51C gene is important for homologous recombination in meiosis and mitosis. Plant Physiol 2005;139:896-908.
-
(2005)
Plant Physiol
, vol.139
, pp. 896-908
-
-
Abe, K.1
Osakabe, K.2
Nakayama, S.3
Endo, M.4
Tagiri, A.5
Todoriki, S.6
-
28
-
-
77951747926
-
Mutation of the RAD51C gene in a Fanconi anemia-like disorder
-
Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V, et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 2010;42:406-9.
-
(2010)
Nat Genet
, vol.42
, pp. 406-409
-
-
Vaz, F.1
Hanenberg, H.2
Schuster, B.3
Barker, K.4
Wiek, C.5
Erven, V.6
-
29
-
-
77951720395
-
Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene
-
Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Nieder-acher D, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010;42:410-4.
-
(2010)
Nat Genet
, vol.42
, pp. 410-414
-
-
Meindl, A.1
Hellebrand, H.2
Wiek, C.3
Erven, V.4
Wappenschmidt, B.5
Nieder-Acher, D.6
-
30
-
-
80052264429
-
Germline mutations in RAD51D confer susceptibility to ovarian cancer
-
Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 2011;43:879-82.
-
(2011)
Nat Genet
, vol.43
, pp. 879-882
-
-
Loveday, C.1
Turnbull, C.2
Ramsay, E.3
Hughes, D.4
Ruark, E.5
Frankum, J.R.6
-
31
-
-
33847307543
-
Role of RAD51C and XRCC3 in genetic recombination and DNA repair
-
Liu Y, Tarsounas M, O'Regan P, West SC. Role of RAD51C and XRCC3 in genetic recombination and DNA repair. J Biol Chem 2007;282: 1973-9.
-
(2007)
J Biol Chem
, vol.282
, pp. 1973-1979
-
-
Liu, Y.1
Tarsounas, M.2
O'Regan, P.3
West, S.C.4
-
32
-
-
78751629661
-
BRCA1 CpG Island hypermethylation predicts sensitivity to poly (adenosine diphosphate)-ribose polymerase inhibitors
-
Veeck J, Ropero S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez J, et al. BRCA1 CpG island hypermethylation predicts sensitivity to poly (adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol 2010;28:e563-4.
-
(2010)
J Clin Oncol
, vol.28
-
-
Veeck, J.1
Ropero, S.2
Setien, F.3
Gonzalez-Suarez, E.4
Osorio, A.5
Benitez, J.6
-
33
-
-
79951887369
-
Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2
-
Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 2011;103:334-46.
-
(2011)
J Natl Cancer Inst
, vol.103
, pp. 334-346
-
-
Drew, Y.1
Mulligan, E.A.2
Vong, W.T.3
Thomas, H.D.4
Kahn, S.5
Kyle, S.6
-
34
-
-
79451472565
-
Require-ment for NBS1 in the S phase checkpoint responseto DNAmethylation combined with PARP inhibition
-
Horton JK, Stefanick DF, Zeng JY, Carrozza MJ, Wilson SH. Require-ment for NBS1 in the S phase checkpoint responseto DNAmethylation combined with PARP inhibition. DNA Repair (Amst) 2011;10:225-34.
-
(2011)
DNA Repair (Amst)
, vol.10
, pp. 225-234
-
-
Horton, J.K.1
Stefanick, D.F.2
Zeng, J.Y.3
Carrozza, M.J.4
Wilson, S.H.5
-
35
-
-
80054765897
-
Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy
-
Ibragimova I, Cairns P. Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy. Methods Mol Biol 2011;780:277-91.
-
(2011)
Methods Mol Biol
, vol.780
, pp. 277-291
-
-
Ibragimova, I.1
Cairns, P.2
-
37
-
-
77957365619
-
Gene promoter hypermethylation in tumors and plasma of breast cancer patients
-
Bae YK, Shim YR, Choi JH, Kim MJ, Gabrielson E, Lee SJ, et al. Gene promoter hypermethylation in tumors and plasma of breast cancer patients. Cancer Res Treat 2005;37:233-40.
-
(2005)
Cancer Res Treat
, vol.37
, pp. 233-240
-
-
Bae, Y.K.1
Shim, Y.R.2
Choi, J.H.3
Kim, M.J.4
Gabrielson, E.5
Lee, S.J.6
|